Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSIX
2024-516715-25-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Oct 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial in Sjögren's syndrome comparing CL-AD-MSC-002 with Placebo (2 arms). Primary endpoint: Change in unstimulated whole saliva flow rate (UFR) from baseline to 4 months. Planned start Oct 2024; status: authorised.
02
Drugs
CL-AD-MSC-002
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2024-516715-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516715-25-00.